Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5398215 | 1.00 | TP53 (0.32) | TP53MDM2 | |
| SCHEMBL5398211 | 1.00 | TP53 (0.32) | TP53MDM2 | |
| SCHEMBL5384999 | 0.90 | TP53 (0.34) | TP53MDM2 | |
| SCHEMBL5395672 | 0.82 | USP2 (0.33) | — | |
| SCHEMBL5397562 | 0.81 | USP2 (0.36) | — | |
| SCHEMBL7248348 | 0.78 | — | — | |
| SCHEMBL7251055 | 0.78 | — | — | |
| SCHEMBL5395938 | 0.77 | TP53 (0.33) | TP53MDM2 | |
| SCHEMBL7248323 | 0.77 | — | — | |
| SCHEMBL7250437 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1475371-A1 | 1-SUBSTITUTED-1-AMINOMETHYL-CYCLOALKANE DERIVATIVES (= GABAPENTIN ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Warner-Lambert Company LLC (US) | 2004-11-10 | — | — | EP | claimed |
| US-20040097405-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2004-05-20 | — | — | US | claimed |
| US-20040006073-A1 | Method of treating attention deficit hyperactivity disorder | DOOLEY DAVID JAMES (US) | 2004-01-08 | — | — | US | claimed |
| US-20030203945-A1 | Heterocyclic derivatives useful as pharmaceutical agents | BLAKEMORE DAVID CLIVE (GB) | 2003-10-30 | — | — | US | claimed |
| US-6518289-B1 | Especially irritable bowel syndrome | PFIZER, INC. | 2003-02-11 | — | — | US | claimed |
| US-20020077342-A1 | Heterocyclic derivatives useful as pharmaceutical agents | WARNER-LAMBERT COMPANY | 2002-06-20 | — | — | US | claimed |
| US-20020072533-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2002-06-13 | — | — | US | claimed |
| EP-1201240-A2 | Heterocyclic derivatives useful as pharmaceutical agents | WARNER-LAMBERT COMPANY (US) | 2002-05-02 | — | — | EP | claimed |
| EP-1199072-A2 | Method of treating cartilage damage | WARNER-LAMBERT COMPANY (US) | 2002-04-24 | — | — | EP | claimed |
| JP-2002508362-A | — | — | 2002-03-19 | — | — | JP | claimed |
| EP-1047678-A1 | 1-SUBSTITUTED-1-AMINOMETHYL-CYCLOALKANE DERIVATIVES (=GABAPENTIN ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Warner-Lambert Company LLC (US) | 2000-11-02 | — | — | EP | claimed |
| WO-1999031075-A1 | 1-SUBSTITUTED-1-AMINOMETHYL-CYCLOALKANE DERIVATIVES (=GABAPENTIN ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | WARNER-LAMBERT COMPANY (US) | 1999-06-24 | — | — | WO | claimed |
| US-20070293570-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070276039-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY LLC (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070213401-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY LLC (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070161707-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | WARNER-LAMBERT COMPANY LLC (US) | 2007-07-12 | — | — | US | disclosed |
| EP-1201240-A2 | Heterocyclic derivatives useful as pharmaceutical agents | WARNER-LAMBERT COMPANY (US) | 2002-05-02 | — | — | EP | disclosed |
| EP-1199072-A2 | Method of treating cartilage damage | WARNER-LAMBERT COMPANY (US) | 2002-04-24 | — | — | EP | disclosed |
| EP-1047678-A1 | 1-SUBSTITUTED-1-AMINOMETHYL-CYCLOALKANE DERIVATIVES (=GABAPENTIN ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Warner-Lambert Company LLC (US) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999031075-A1 | 1-SUBSTITUTED-1-AMINOMETHYL-CYCLOALKANE DERIVATIVES (=GABAPENTIN ANALOGUES), THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | WARNER-LAMBERT COMPANY (US) | 1999-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213401-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | TP53 4334/4885MDM2 4505/4885 |
| US-20070293570-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | TP53 4334/4885MDM2 4505/4885 |
| US-20020072533-A1 | Method of treating cartilage damage | COL2A1, COL1A1, GABRB1 | TP53 1913/4885MDM2 2661/4885 |
| US-20070161707-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | TP53 4334/4885MDM2 4505/4885 |
| US-20070276039-A1 | PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS | ADRA2A, ADRA1D, OPRD1 | TP53 4334/4885MDM2 4505/4885 |
| US-20020077342-A1 | Heterocyclic derivatives useful as pharmaceutical agents | CNR1, SUCNR1, CACNA1A | TP53 4736/4885MDM2 4737/4885 |
| US-20030203945-A1 | Heterocyclic derivatives useful as pharmaceutical agents | CNR1, SUCNR1, CACNA1A | TP53 4736/4885MDM2 4737/4885 |
| US-20040097405-A1 | Method of treating cartilage damage | COL2A1, COL1A1, GABRB1 | TP53 1913/4885MDM2 2661/4885 |
| US-20040006073-A1 | Method of treating attention deficit hyperactivity disorder | GABRB2, GABBR1, GABBR2 | TP53 4613/4885MDM2 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.